•Insmed posted its second-quarter 2014 net loss of $23.2 million, or $0.59 per share, compared to a net loss of $8.9 million, or $0.28 per share, in the year-ago period.
•R&D expenses in the second quarter of 2014 increased to $14.9 million from $12.2 million in the second quarter of 2013.
•Insmed's rising R&D expense was indicative of the fact that the company might be successfully developing ARIKAYCE, its lead drug.
•Insmed just announced that it has priced an offering of 8.9 million shares of its common stock at $11.25 per share.
Insmed (NASDAQ:INSM) posted a net loss of $23.2 million, or $0.59 per share, for the second quarter of 2014, compared to a net loss of $8.9 million, or $0.28 per share, in the same period of the prior year. The company's net loss increased because in the year-ago quarter, the company received $11.5 million in other revenue related to a one-time payment for the sale of the company's right to receive future royalties under its license agreement with Premacure (now Shire plc). Higher expenses in the second quarter of 2014 also resulted in widening of net loss.
The company's lead product, ARIKAYCE (inhaled liposomal amikacin), will provide effective treatment to patients battling orphan lung diseases. Currently, amikacin is delivered intravenously, but with ARIKAYCE, it can be delivered directly to the site of disease using an investigational delivery system known as eFlow electronic nebulizer manufactured by PARI Pharma GmbH. The company announced at the time of reporting its second-quarter results that it plans to file a Market Authorization Application ("MAA") with the European Medicines Agency ("EMA") for ARIKAYCE. Will Lewis, president and CEO of Insmed, said, "With the recent regulatory clarity, we are moving forward with preparation for commercialization in Europe while simultaneously advancing our two global NTM studies."..."Currently, the stock is trading around $13, I believe it has meaningful upside in the near term"